Efficacy and safety of spleen tyrosine kinase inhibitors in chronic immune thrombocytopenic purpura: A meta-analysis of randomized controlled trials

作者
Faisal Rasheed,Abat Khan,Saba Musleh Ud Din,Maheen Zaidi,Muhammad Asad Ayub,Atif Mahmoud Hussein
出处
期刊:Blood [Elsevier BV]
卷期号:146 (Supplement 1): 6589-6589 被引量:1
标识
DOI:10.1182/blood-2025-6589
摘要

Abstract Background: Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by persistent low platelet counts. While thrombopoietin receptor agonists (TPO-RAs) are effective, they are associated with thrombotic complications. Spleen tyrosine kinase (SYK) inhibitors represent a novel class of agents targeting immune-mediated platelet destruction, with a potentially favorable safety profile. We conducted a meta-analysis of randomized controlled trials (RCTs) comparing SYK inhibitors to placebo in patients with chronic ITP. Methods: We searched PubMed, Embase, Cochrane Library, and Web of Science through July 2025 for RCTs evaluating fostamatinib or sovleplenib versus placebo in adults with chronic ITP. Data were pooled using Review Manager (RevMan) under a random-effects model. Risk ratios (RR) with 95% confidence intervals (CI) were calculated. The primary endpoint was durable response, defined as platelet count ≥30–50 × 10⁹/L on ≥4 of 6 scheduled visits or ≥80% of visits. Secondary endpoints included overall response and safety outcomes. Results: Five RCTs were included: three evaluated fostamatinib and two evaluated sovleplenib. Compared to placebo, SYK inhibitors significantly improved durable response (RR 8.64; 95% CI, not reported; p < 0.0001; I² = 0%). Subgroup analysis showed durable response was higher with both fostamatinib (RR 6.47; p = 0.009; I² = 0%) and sovleplenib (RR 15.88; p = 0.04; I² = 60%). Overall response rates were also higher in the SYK group (RR 3.69; p < 0.001; I² = 0%). Treatment-emergent adverse events (TEAEs) were more frequent with SYK inhibitors (RR 1.18; p = 0.07; I² = 56%), but the difference was not statistically significant. Adverse events leading to dose reduction or discontinuation were also slightly higher in the SYK group (RR 1.05; p = 0.92; I² = 0%). No thrombotic events were reported in any SYK inhibitor arm. Conclusion: SYK inhibitors significantly improve platelet response in chronic ITP without increased thrombotic risk. Fostamatinib and the investigational agent sovleplenib both demonstrated efficacy compared to placebo. These agents may represent promising options for patients with refractory ITP, particularly those at risk of thrombosis from TPO-RAs. Further head-to-head studies comparing SYK inhibitors to standard second-line therapies are warranted.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
书生完成签到,获得积分10
3秒前
张倾情完成签到,获得积分10
3秒前
翻斗花园吴靓靓完成签到 ,获得积分10
4秒前
Anatee完成签到,获得积分10
4秒前
忧伤的平安完成签到,获得积分10
7秒前
情怀的应助被帆320采纳,获得10
8秒前
8秒前
kevin完成签到,获得积分10
8秒前
Wei完成签到,获得积分10
12秒前
王kk完成签到 ,获得积分10
13秒前
海风完成签到,获得积分10
14秒前
辛辛那提完成签到,获得积分10
16秒前
乐无忧完成签到 ,获得积分10
16秒前
炳灿完成签到 ,获得积分10
19秒前
Skywalk满天星完成签到,获得积分10
19秒前
烂漫向梦完成签到,获得积分10
20秒前
21秒前
jie完成签到 ,获得积分10
22秒前
优雅的盼旋完成签到,获得积分10
23秒前
孤独的问柳完成签到,获得积分10
25秒前
烂漫向梦发布了新的文献求助10
25秒前
26秒前
小可爱完成签到,获得积分10
28秒前
称心忆灵完成签到,获得积分10
30秒前
leo完成签到,获得积分10
32秒前
32秒前
水本无忧87完成签到,获得积分0
32秒前
32秒前
不安丹云完成签到,获得积分10
34秒前
英姑的应助被酷酷的怀莲采纳,获得10
35秒前
忽忽完成签到,获得积分10
35秒前
小梅超顺利完成签到 ,获得积分10
35秒前
Wang完成签到 ,获得积分10
35秒前
众行绘研完成签到 ,获得积分10
36秒前
ronnie完成签到,获得积分10
36秒前
37秒前
帆320发布了新的文献求助10
37秒前
碧蓝的绿草完成签到 ,获得积分10
39秒前
雪白若颜完成签到 ,获得积分10
40秒前
weijinfen完成签到,获得积分10
40秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166556
求助须知:如何正确求助?哪些是违规求助? 9559576
关于积分的说明 21750809
捐赠科研通 7757392
什么是DOI,文献DOI怎么找? 3429167
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923